Skip to content
Ejaculation.org

Meta-analysis · 2025

Botulinum toxin-A is ineffective in premature ejaculation treatment: insights from a meta-analysis of randomised controlled trials

Mubarak M, Isa Q, Modgil V, Pearce I (2025). Botulinum toxin-A is ineffective in premature ejaculation treatment: insights from a meta-analysis of randomised controlled trials. International Journal of Impotence Research. doi:10.1038/s41443-025-01022-9

Key finding
In three RCTs (228 men), botulinum toxin injected into the bulbospongiosus muscle did not significantly improve latency or PE Profile scores versus saline; complications occurred in 9.6%, mostly voiding difficulty and mild erection problems.

Summary

Botulinum toxin-A relaxes muscle, and injecting it into the bulbospongiosus muscle (a pelvic floor muscle that contracts during the expulsion phase of ejaculation) has been proposed to delay ejaculation. The authors pooled randomised controlled trials comparing 100 units of botulinum toxin-A with saline, following PRISMA methods and grading the certainty of evidence.

Three trials with 228 patients were eligible. Average latency gains were 39.6, 11.5 and 2.4 seconds at 1, 3 and 6 months, and Premature Ejaculation Profile (PEP) scores improved slightly, but neither outcome was statistically significant. Complications occurred in 11 patients (9.6%), 10 of them in the toxin group, mostly voiding difficulties and mild erectile dysfunction, all of which resolved without treatment.

Limitations

Only three trials were available. Another 2025 meta-analysis of three trials found a statistically significant short-term benefit at one month that faded by three months, so the overall picture is of small, short-lived effects at best.

What it means for you

Current high-quality evidence does not support botulinum toxin injections for premature ejaculation. Any effect seen in trials was small and wore off within months.